(NASDAQ: AMRN) Amarin's forecast annual revenue growth rate of -0.08% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.3%.
Amarin's revenue in 2026 is $176,112,000.On average, 4 Wall Street analysts forecast AMRN's revenue for 2026 to be $76,205,047,776, with the lowest AMRN revenue forecast at $70,852,445,006, and the highest AMRN revenue forecast at $80,984,458,438. On average, 4 Wall Street analysts forecast AMRN's revenue for 2027 to be $76,011,173,975, with the lowest AMRN revenue forecast at $67,999,128,412, and the highest AMRN revenue forecast at $83,639,686,583.
In 2028, AMRN is forecast to generate $73,705,761,601 in revenue, with the lowest revenue forecast at $65,217,460,831 and the highest revenue forecast at $81,869,534,486.